News
Jupiter Endovascular announced today that its Vertex catheter received FDA 510(k) clearance for the insertion of endovascular ...
Zacks Investment Research on MSN
Vertex Plunges Around 24% in Six Months: How to Play the Stock
Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $387.15, moving -1.08% from the previous trading session. This change lagged the S&P 500's daily loss of 0.1%. Meanwhile, the Dow ...
Vertex Pharmaceuticals Incorporated just reported a robust Q2 with earnings per share of $4.52, surpassing estimates and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback